China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
NEW YORK, March 24, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Columbia on behalf of investors who purchased Mallinckrodt plc (NYSE:MNK) securities between July 14, 2014, and January 18, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/mallinckrodt-plc. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, Mallinckrodt and its acting President and Chief Executive Officer, Mark Trudeau, misrepresented the efficacy of Mallinckrodt’s business model and its ability to maintain sustainable revenue. Specifically, the complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that Mallinckrodt engaged in unlawful anticompetitive practices to maintain H.P. Acthar Gel’s (“Acthar”) monopoly status as the only FDA-approved therapeutic preparation of adrenocorticotropic hormone and that Mallinckrodt’s increasing reliance on Medicare and Medicaid meant that the Company’s monopolistic Acthar revenue would be threatened if the government took action to limit the price paid for the drug by taxpayers.
If you suffered a loss in Mallinckrodt you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/mallinckrodt-plc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
